According to the current guidelines for RA treatment published by EULAR and ACR, JAKis, TNF inhibitors, and non-TNF inhibitors are recommended for csDMARD-IR patients equally by shared decision-making process [9,10]. Here, TNF is linked to rheumatoid arthritis.